Literature DB >> 23712721

Treatment resistant depression: strategies for primary care.

Taylor C Preston1, Richard C Shelton.   

Abstract

Depression is commonly diagnosed and treated in primary care. Recent evidence indicates that the majority of depressed patients will not fully recover with an initial antidepressant treatment. This paper reviews commonly used options for treatment after an inadequate initial antidepressant response. The alternatives range widely, and include escalating the dose of the initial antidepressant, switching to an alternative medication, combining two antidepressants with different mechanisms of action (e.g., bupropion + SSRI or mirtazapine + venlafaxine), adding other medications such as lithium or certain atypical antipsychotics (olanzapine, aripiprazole, or quetiapine) to the antidepressant, adding a natural product such as l-methylfolate or s-adenosylmethionine (SAMe), or adding cognitive behavioral psychotherapy. What agent to be used will depend on the comfort level of the primary care practitioner and the availability of Psychiatry referral. However, it is reasonable to take one or more additional steps to attempt to achieve remission.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23712721     DOI: 10.1007/s11920-013-0370-7

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  29 in total

1.  Sponsorship, antidepressant dose, and outcome in major depressive disorder: meta-analysis of randomized controlled trials.

Authors:  Mark Sinyor; Ayal Schaffer; Kelly A Smart; Anthony J Levitt; Krista L Lanctôt; Noam H Grysman
Journal:  J Clin Psychiatry       Date:  2012-02       Impact factor: 4.384

2.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

3.  Outcomes of "inadequate" antidepressant treatment.

Authors:  G E Simon; E H Lin; W Katon; K Saunders; M VonKorff; E Walker; T Bush; P Robinson
Journal:  J Gen Intern Med       Date:  1995-12       Impact factor: 5.128

Review 4.  Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report.

Authors:  Marlene P Freeman; Maurizio Fava; James Lake; Madhukar H Trivedi; Katherine L Wisner; David Mischoulon
Journal:  J Clin Psychiatry       Date:  2010-06       Impact factor: 4.384

5.  A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression.

Authors:  J C Nelson; C M Mazure; M B Bowers; P I Jatlow
Journal:  Arch Gen Psychiatry       Date:  1991-04

6.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

7.  A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants.

Authors:  Charles DeBattista; H Brent Solvason; Jennifer Poirier; Ellen Kendrick; Alan F Schatzberg
Journal:  J Clin Psychopharmacol       Date:  2003-02       Impact factor: 3.153

Review 8.  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Authors:  Christoph U Correll; Stefan Leucht; John M Kane
Journal:  Am J Psychiatry       Date:  2004-03       Impact factor: 18.112

9.  Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study.

Authors:  J Craig Nelson; Carolyn M Mazure; Peter I Jatlow; Malcolm B Bowers; Lawrence H Price
Journal:  Biol Psychiatry       Date:  2004-02-01       Impact factor: 13.382

10.  Patterns of antidepressant use in community practice.

Authors:  G E Simon; M VonKorff; E H Wagner; W Barlow
Journal:  Gen Hosp Psychiatry       Date:  1993-11       Impact factor: 3.238

View more
  8 in total

1.  BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder.

Authors:  Lawrence R Marcin; Jayakumar Warrier; Srinivasan Thangathirupathy; Jianliang Shi; George N Karageorge; Bradley C Pearce; Alicia Ng; Hyunsoo Park; James Kempson; Jianqing Li; Huiping Zhang; Arvind Mathur; Aliphedi B Reddy; G Nagaraju; Gopikishan Tonukunuru; Grandhi V R K M Gupta; Manjunatha Kamble; Raju Mannoori; Srinivas Cheruku; Srinivas Jogi; Jyoti Gulia; Tanmaya Bastia; Charulatha Sanmathi; Jayant Aher; Rajareddy Kallem; Bettadapura N Srikumar; Kumar Kuchibhotla Vijaya; Pattipati S Naidu; Mahesh Paschapur; Narasimharaju Kalidindi; Reeba Vikramadithyan; Manjunath Ramarao; Rex Denton; Thaddeus Molski; Eric Shields; Murali Subramanian; Xiaoliang Zhuo; Michelle Nophsker; Jean Simmermacher; Michael Sinz; Charlie Albright; Linda J Bristow; Imadul Islam; Joanne J Bronson; Richard E Olson; Dalton King; Lorin A Thompson; John E Macor
Journal:  ACS Med Chem Lett       Date:  2018-04-13       Impact factor: 4.345

2.  Antidepressant-like effect of Campomanesia xanthocarpa seeds in mice: Involvement of the monoaminergic system.

Authors:  Gabriela Sabrina Anzollin; Lilian Zaki; Thalita Maria Perin; Bruna Finger; Letícia Trentin Perin; Fernanda Petry; Thalia Sebulsqui Saraiva; Maria Luiza Lima da Costa Lopes; Andresa Heemann Betti; Jaqueline Scapinello; J Vladimir Oliveira; Jacir Dal Magro; Liz G Müller
Journal:  J Tradit Complement Med       Date:  2021-08-30

3.  Expression of the 5-HT1A serotonin receptor in the hippocampus is required for social stress resilience and the antidepressant-like effects induced by the nicotinic partial agonist cytisine.

Authors:  Yann S Mineur; Emily B Einstein; Matthew P Bentham; Mattis B Wigestrand; Sam Blakeman; Sylvia A Newbold; Marina R Picciotto
Journal:  Neuropsychopharmacology       Date:  2014-10-07       Impact factor: 7.853

Review 4.  Abuse and misuse of antidepressants.

Authors:  Elizabeth A Evans; Maria A Sullivan
Journal:  Subst Abuse Rehabil       Date:  2014-08-14

Review 5.  Major depressive disorder: mechanism-based prescribing for personalized medicine.

Authors:  Philip F Saltiel; Daniel I Silvershein
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-31       Impact factor: 2.570

Review 6.  The Role of the Patient-Centered Medical Home in Treating Depression.

Authors:  Olivia E Bogucki; Mark D Williams; Leif I Solberg; Rebecca C Rossom; Craig N Sawchuk
Journal:  Curr Psychiatry Rep       Date:  2020-07-14       Impact factor: 5.285

7.  Antidepressant-like effects of acupuncture involved the ERK signaling pathway in rats.

Authors:  Xuhui Zhang; Yingzhou Song; Tuya Bao; Miao Yu; Mingmin Xu; Yu Guo; Yu Wang; Chuntao Zhang; Bingcong Zhao
Journal:  BMC Complement Altern Med       Date:  2016-09-29       Impact factor: 3.659

8.  Adipose-derived mesenchymal stem cells protect against CMS-induced depression-like behaviors in mice via regulating the Nrf2/HO-1 and TLR4/NF-κB signaling pathways.

Authors:  Xiao Huang; Guo-Qiang Fei; Wen-Juan Liu; Jing Ding; Yuan Wang; Hao Wang; Jian-Lin Ji; Xin Wang
Journal:  Acta Pharmacol Sin       Date:  2019-12-03       Impact factor: 6.150

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.